A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer

• 資料種別: 博士論文
• タイトル: A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer
• 著者・編者: Goji, Takahiro; Kimura, Tetsuo; Miyamoto, Hiroshi; Takehara, Masanori; Kagemoto, Kaizo; Okada, Yasuyuki; Okazaki, Jun; Takaoka, Yoshifumi; Miyamoto, Yoshihiko; Mitsui, Yasuhiro; Matsumoto, Sayo; Sueuchi, Tatsuhisa; Tanaka, Kumiko; Fujino, Yasuteru; Takaoka, Toshi; Kitamura, Shinji; Okamoto, Koichi; Kimura, Masako; Sogabe, Masahiro; Muguruma, Naoki; Okahisa, Toshiya; Sato, Yasuhiro; Sagawa, Tamotsu; Fujikawa, Koji; Sato, Yasushi; Ikushima, Hitoshi; Takayama, Tetsuji
• 著者標目: Goji, Takahiro; Kimura, Tetsuo; Miyamoto, Hiroshi; Takehara, Masanori; Kagemoto, Kaizo; Okada, Yasuyuki; Okazaki, Jun; Takaoka, Yoshifumi; Miyamoto, Yoshihiko; Mitsui, Yasuhiro; Matsumoto, Sayo; Sueuchi, Tatsuhisa; Tanaka, Kumiko; Fujino, Yasuteru; Takaoka, Toshi; Kitamura, Shinji; Okamoto, Koichi; Kimura, Masako; Sogabe, Masahiro; Muguruma, Naoki; Okahisa, Toshiya; Sato, Yasuhiro; Sagawa, Tamotsu; Fujikawa, Koji; Sato, Yasushi; Ikushima, Hitoshi; Takayama, Tetsuji
• 出版事項: Springer nature
• 出版年月日等: 2015-07-29
• 出版年（W3CDTF）: 2015-07-29
• 並列タイトル等: 局所進行膵癌に対するゲムシタビン定速静注及びS-1併用化学放射線療法の第Ⅰ/Ⅱ相試験; FDR-gem plus S-1 with RT for pancreatic cancer
• タイトル（掲載誌）: Cancer Chemotherapy and Pharmacology
• 巻号年月日等（掲載誌）: 76 3
• 掲載巻: 76
• 掲載号: 3
• 掲載ページ: 615-620
• ISSN（掲載誌）: ISSN : 0344-5704; ISSN : 1432-0843
• 授与機関名: 徳島大学
• 授与年月日: 2017-03-23
• 報告番号: 甲第3028号
• 学位: 博士（医学）
• 本文の言語コード: eng
• 件名標目: Pancreatic cancer; Chemoradiotherapy; Fixed-dose-rate gemcitabine; S-1; gemcitabine; radiosensitizer
• 対象利用者: 一般
• 一般注記: Purpose: This study was conducted to identify the maximum-tolerated dose (MTD) of fixed-dose-rate gemcitabine (FDR-gem) administered concurrently with S-1 and radical radiation for locally advanced pancreatic cancer (LAPC) and to provide efficacy and safety data. Methods: Patients with unresectable pancreatic cancer confined to the pancreatic region were treated with FDR-gem (300-400mg/m2, 5mg/m2/min) on days 1, 8, 22, 29 and 60mg/m2 of S-1 orally on days 1-14, 22-35. A total radiation dose of 50.4 Gy (1.8 Gy/day, 28fractions) was delivered concurrently. Results: Twenty-five patients were enrolled; all were evaluable for toxicity assessment. In phase I, eight patients were treated in sequential cohorts of three to five patients per dose level. The MTD was reached at level 2, and dose-limiting toxicities were neutropenia and thrombocytopenia. The recommended doses were 300mg/m2 of gemcitabine and 60mg/m2 of S-1 daily. The overall response rate was 25% and disease control rate (partial response plus stable disease) was 92%. The progression-free survival was 11.0 months. The median overall survival and 1-year survival rate were 16.0 months and 73%, respectively. Conclusion: The combination of FDR-gem and S-1 with radiation is a feasible regimen that shows favorable antitumor activity with an acceptable safety profile in patients with LAPC.
• 記録形式（IMT）: application/pdf
• オンライン閲覧公開範囲: インターネット公開
• 関連情報（DOI）: 10.1007/s00280-015-2835-3
• 連携機関・データベース: 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• 提供元機関・データベース: 徳島大学 : 徳島大学機関リポジトリ

目次

http://repo.lib.tokushima-u.ac.jp/files/public/11/110046/20170929142602211579/LID201704141008.pdf fulltext

http://repo.lib.tokushima-u.ac.jp/files/public/11/110046/20180308141019248985/k3028_fulltext.pdf fulltext